TABLE 4

Peak characteristics

PeakPeak characteristicsAlveolar gradient V
RT s1/K0 V·cm−2HCAExARDBLDLCMPMp-value#
P0282.10.6680.0019 (−0.0003;0.0066)0.0002 (−0.0008;0.0012)0.0000 (−0.0022;0.0017)−0.0005 (−0.0019;0.0010)0.0007 (−0.0002;0.0031)−0.0005 (−0.0018;0.0016)<0.001
P15.90.5030.0354 (0.0070;0.0597)0.0948 (0.669;0.1277)0.0904 (0.0405;0.1274)0.0746 (0.0482;0.1043)0.0507 (0.0261;0.0665)0.0350 (0.0179;0.0688)<0.001
P36.70.5440.0333 (0.0003;0.0786)0.0766 (0.0622;0.1026)0.0588 (0.0370;0.0922)0.0416 (0.0073;0.0660)0.0383 (0.0030;0.0669)0.0363 (0.0039;0.0672)<0.001
P76.60.5780.0158 (0.0064;0.0265)0.0168 (0.0093;0.0323)0.0202 (0.0109;0.0288)0.0108 (0.0015;0.0275)0.0068 (−0.0012;0.0272)0.0083 (−0.0038;0.0297)NS
P91.60.6010.0083 (0.0005;0.0270)0.0032 (−0.0002;0.0067)0.0045 (0.0005;0.0068)−0.0007 (−0.0121;0.0044)0.0018 (−0.0052;0.0052)0.0070 (0.0021;0.0192)<0.001
P154.50.715−0.0012 (−0.0036;0.0027)−0.0027 (−0.0050;0.0015)−0.0022 (−0.0061;0.007)0.0020 (−0.0015;0.0040)−0.0042 (−0.0091;−0.0001)−0.0053 (−0.0090;−0.0017)<0.001
P211.20.514−0.0250 (−0.0661;−0.032)−0.0039 (−0.0481;0.0420)−0.0341 (−0.0540;0.0201)−0.0518 (−0.0768;−0.0201)−0.0464 (−0.0679;−0.0175)−0.0499 (−0.0853;−0.0258)NS
P264.20.6890.0040 (−0.0024;0.0121)0.0045 (0.0007;0.0186)0.0063 (0.0016;0.0245)0.0055 (0.0028;0.0073)0.0036 (−0.0005;0.0068)0.0024 (0.0001;0.0117)<0.001
P424.50.457−0.1371 (−0.2189;−0.0841)−0.2069 (−0.2878;−0.0951)−0.2364 (−0.3166;−0.0887)0.0035 (−0.0543;0.0485)−0.1551 (−0.2243;−0.0387)−0.2212 (−0.2969;−0.0912)<0.001
P6666.50.733−0.0057 (−0.0125;0.0003)−0.0149 (−0.0206;−0.0080)−0.0111 (−0.0201;−0.0066)−0.0052 (−0.0114;−0.0024)−0.0124 (−0.0178;−0.0070)−0.0100 (−0.0209;−0.0039)<0.001
P83160.60.764−0.0009 (−0.0026;0.0003)−0.0028 (−0.0044;−0.0016)−0.0041 (−0.0048;−0.0015)−0.0011 (−0.0023;−0.0001)−0.0027 (−0.0047;−0.0010)−0.0022 (−0.0038;−1.0006)<0.001
P84116.10.7420.0001 (−0.0006;0.0008)−0.0010 (−0.0024;−0.0004)−0.0002 (−0.0015;0.0004)0.0003 (−0.0004;0.0009)−0.0001 (−0.0009;0.0007)−0.0002 (−0.0011;0.0007)<0.001
P885.50.6570.0013 (−0.0003;0.0037)0.0011 (−0.0011;0.0027)0.0014 (−0.0002;0.0032)−0.0007 (−0.0025;0.0022)0.0004 (−0.0049;0.0023)0.0009 (−0.0030;0.0032)NS
P10120.00.716−0.0007 (−0.0037;0.0025)−0.0122 (−0.0216;−0.0028)−0.0100 (−0.0166;−0.0025)−0.0033 (−0.0062;−0.0001)−0.0042 (−0.0072;−0.0010)−0.0008 (−0.0041;0.0002)<0.001
P11499.80.728−0.0001 (−0.0009;0.0007)−0.0009 (−0.0023;−0.0002)−0.0004 (−0.0017;0.0001)−0.0001 (−0.0008;0.0004)−0.0005 (−0.0011;0.0002)−0.0003 (−0.0014;0.0004)0.025
P11598.70.6650.0004 (−0.0005;0.0012)−0.0009 (−0.0029;0.0002)−0.0009 (−0.0031;−0.0002)0.0000 (−0.0010;0.0007)−0.0004 (−0.0012;0.0007)−0.0006 (−0.0015;0.0005)<0.001
P118184.60.639−0.0001 (−0.0006;0.0005)−0.0006 (−0.0014;0.0000)−0.0005 (−0.0011;0.0003)−0.0003 (−0.0007;0.0003)−0.0003 (−0.0010;0.0004)−0.0001 (−0.0007;0.0007)NS
P12367.10.759−0.0011 (−0.0030;0.0005)−0.0049 (−0.0091;−0.0023)−0.0044 (−0.0074;−0.0027)−0.0019 (−0.0039;−0.0008)−0.0042 (−0.0074;−0.0016)−0.0033 (−0.0046;−0.0014)<0.0001
P13634.60.9100.0002 (−0.0009;0.0009)−0.0004 (−0.0007;0.0004)−0.0002 (−0.0006;0.0003)0.0001 (−0.0004;0.0006)−0.0003 (−0.0009;0.0004)−0.0004 (−0.0010;0.0003)NS
P212138.10.771−0.0001 (−0.0005;0.0008)−0.0003 (−0.0016;0.0007)−0.0004 (−0.0014;0.0001)−0.0002 (−0.0006;0.0003)0.0001 (−0.0005;0.0005)0.0002 (−0.0009;0.0009)NS
P223309.10.601−0.0005 (−0.0012;0.0001)0.0000 (−0.0005;0.0005)0.0002 (−0.0006;0.0006)0.0001 (−0.0005;0.0008)−0.0001 (−0.0005;−0.0005)−0.0001 (−0.0009;0.0005)NS
P2374.50.7000.0020 (−0.0004;0.0046)0.0018 (−0.0007;0.0038)0.0025 (−0.0006;0.0055)0.0012 (−0.0004;0.0034)0.0019 (−0.0001;0.0043)0.0015 (−0.0005;0.0061)NS
P24413.50.917−0.0001 (−0.0009;0.0008)−0.0004 (−0.0013;0.0003)−0.0001 (−0.0008;0.0002)−0.0004 (−0.0010;0.0002)−0.0006 (−0.0017;0.0002)−0.0004 (−0.0012;0.0009)NS

Data as presented as median (Q1;Q3). RT: retention time; 1/K0: inverse reduced ion mobility; AEx: asymptomatic former asbestos workers; ARD: patients with benign asbestos-related diseases; BLD: patients with benign, non-asbestos-related diseases; HC: healthy control participants without asbestos exposure; LC: patients with lung cancer; MPM: patients with malignant pleural mesothelioma; #: Kruskal–Wallis test.